Immunomodulatory effects of nanomaterials : assessment and analysis /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Elsabahy, Mahmoud (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, MA ; Kidlington, OX, United Kingdom : Woodhead Publishing, [2022]
Colección:Woodhead Publishing series in biomaterials.
Temas:
Biomedical materials.
Nanostructured materials > Toxicology.
Nanostructured materials > Physiological effect.
Biomat�eriaux.
Nanomat�eriaux > Toxicologie.
Nanomat�eriaux > Effets physiologiques.
Biomedical materials
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front Cover
  • Immunomodulatory Effects of Nanomaterials
  • Copyright Page
  • Contents
  • List of contributors
  • About the editor
  • Preface
  • Acknowledgments
  • Introduction
  • 1 Nanomaterials: classification, composition, and recent advances in synthesis
  • 1.1 Introduction to nanotechnology
  • 1.2 Terminology of nanotechnology
  • 1.3 Unique properties of nanomaterials
  • 1.4 Classification of nanomaterials
  • 1.4.1 Polymeric nanoparticles
  • 1.4.2 Nanoemulsions
  • 1.4.3 Inorganic nanoparticles
  • 1.4.4 Carbonaceous nanomaterials
  • 1.5 Nanomaterial synthesis
  • 1.6 Characterization of nanomaterials
  • 1.6.1 Stability and surface chemistry
  • 1.6.2 Particle size measurement and polydispersity
  • 1.6.3 Electron microscopy and imaging
  • 1.6.4 Ultraviolet-visible spectroscopy
  • 1.7 Concluding remarks and future avenue
  • References
  • 2 Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19*
  • 2.1 Coronavirus disease-2019
  • 2.2 Morphological structure and genome
  • 2.3 Clinical presentation, radiological features, and laboratory investigations
  • 2.4 Therapeutic attempts
  • 2.5 Antiviral therapy
  • 2.6 Lopinavir/ritonavir and Arbidol
  • 2.7 Immune therapy
  • 2.7.1 Convalescent plasma therapy
  • 2.8 Tocilizumab
  • 2.9 Bamlanivimab (LY3819253 or LY-CoV555) and Etesevimab (LY3832479 or LY-CoV016)
  • 2.10 Casirivimab (previously REGN10933) and imdevimab (previously REGN10987)
  • 2.11 JAK inhibitors
  • 2.12 Baricitinib
  • 2.13 Ruxolitinib
  • 2.14 Jakotinib
  • 2.15 Vaccines
  • 2.16 Nanoengineered therapeutics and vaccines in development for management of COVID-19
  • 2.16.1 Nanoengineered therapeutics
  • 2.16.2 Nanoengineered vaccines
  • 2.17 Current status and perspectives
  • Acknowledgment
  • References
  • 3 Nanomaterials and immune system*
  • 3.1 Introduction
  • 3.2 The immune system.
  • 3.2.1 Structure of the immune system
  • 3.2.2 Proinflammatory cytokines
  • 3.3 Nanomaterials
  • 3.4 Cytokines as biomarkers of immunomodulatory properties of nanomaterials
  • 3.4.1 Proinflammatory cytokines as biomarkers of nanoparticle immunotoxicity
  • 3.4.2 Route of administration
  • 3.4.2.1 Intravenous route
  • 3.4.2.2 Subcutaneous and dermal routes
  • 3.4.2.3 Nasal and oral routes
  • 3.4.2.4 Intraperitoneal
  • 3.4.3 Endocytic pathways
  • 3.4.4 The role of the nanocarriers: physicochemical characteristics
  • 3.4.4.1 Size
  • 3.4.4.2 Shape and hydrophobicity
  • 3.4.4.3 Composition and surface modifications
  • 3.4.5 The contribution of the payloads
  • 3.5 Mechanisms of nanoparticle immunotoxicity
  • 3.6 Relationship between cytokines and adverse reactions
  • 3.7 Evaluation of nanoparticle immunotoxicity
  • 3.7.1 Multiplexing principles and complications
  • 3.7.1.1 Principles
  • 3.7.1.2 Complications
  • 3.8 Controlling the immunotoxicity of nanomaterials
  • 3.8.1 Nanoparticle-related factors
  • 3.8.2 Drug-related factors
  • 3.9 Conclusions
  • References
  • 4 Methods for evaluation of the immunomodulatory effects of nanoparticles*
  • 4.1 Introduction
  • 4.2 Multiplexing technique for evaluation of particulate materials
  • 4.3 Preassessment step: optional
  • 4.4 Data mining and analysis
  • References
  • 5 Recommendations and use of multiplex biomarker assays
  • 5.1 Introduction
  • 5.1.1 Evaluation of multiplex assays
  • 5.1.1.1 Selecting the right size of multiplex assay
  • 5.1.1.2 Effects of sample matrix
  • 5.1.1.3 Reproducibility
  • 5.1.1.4 Lot-to-lot variability
  • 5.1.2 Unique challenges with multiplexed assays
  • 5.1.2.1 Finding the best sample dilution scheme
  • 5.1.2.2 Cross-reactivity in multiplexed assays
  • 5.1.2.3 Challenges of crosstalk
  • 5.1.2.4 Fit for purpose validation of multiplex assays
  • 5.1.2.5 Assay sensitivity.
  • 5.2 Conclusions
  • References
  • 6 Precautions during evaluation of immunotoxicity of particulate materials*
  • References
  • 7 Data analysis and interpretation*
  • 7.1 Discussion
  • 7.2 Method
  • References
  • Index
  • Back Cover.

Ejemplares similares